Sr. Director, Patient Marketing Dual Asset Strategy

Senior Director, Patient Marketing & Commercial Strategy MMN-CIDP Franchise

Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.

We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients.

The Senior Director, Patient Marketing & Commercial Strategy MMN-CIDP Franchise is a senior commercial leader accountable for maximizing growth of Vyvgart Hytrulo in CIDP while strategically preparing for and integrating the launch of Empa in MMN and subsequently CIDP, within a multi-indication therapeutic franchise.

This role sits on the CIDP Indication Strategy Team and JIST, and owns the patient commercial strategy across the portfolio, with primary responsibility for accelerating performance, expanding reach, and strengthening positioning of Vyvgart Hytrulo in CIDP. In parallel, this leader will work with ICTs and cross-functional partners to define the dual-asset strategy and co-positioning framework to ensure the upcoming Empa launch in MMN and CIDP enhances franchise value.

Success in this role requires balancing revenue growth for Vyvgart Hytrulo with long-term CIDP-MMN portfolio strategy, shaping the market to expand category demand, and building a cohesive enterprise narrative that maximizes total franchise growth.

Key Responsibilities

I. Maximize Growth Trajectory and Peak Revenue of Vyvgart in CIDP (Primary)

• Lead the development and evolution of patient commercial strategy to maximize growth across CIDP and MMN.
• Identify and unlock growth levers across awareness, consideration, therapy initiation, persistence, and lifecycle management.
• Strengthen competitive positioning and reinforce differentiated value within the treatment paradigm.
• Drive omnichannel optimization using rigorous performance analytics and agile measurement.
• Expand addressable market through targeted patient segment strategies and ecosystem partnerships.
• Partner closely with HCP, Market Access, Medical, Patient Support Services and Patient Advocacy to remove friction points across the patient journey.
• Co-Lead proactive competitive response planning and scenario modeling.

II. Architect Dual-Asset Co-Positioning Strategy

• Define clear roles, positioning, and treatment sequencing for Vyvgart and Empa across CIDP and MMN.
• Develop a franchise-level value narrative that clarifies differentiation while reinforcing complementary strengths.
• Prevent internal cannibalization through disciplined segmentation and treatment pathway strategy.
• Establish guardrails for patient engagement, messaging, targeting, and lifecycle investment decisions.
• Lead trade-off discussions to optimize enterprise value versus individual brand preference.

III. Shape the Market to Expand Total Franchise Value

• Drive market shaping initiatives that grow category awareness and demand
• Lead disease awareness and unbranded education strategies to increase top-of-funnel volume.
• Identify structural barriers (diagnostic delay, access constraints, patient inertia) and design strategic interventions.
• Influence evidence generation priorities in partnership with Medical and Development to support long-term differentiation.
• Anticipate competitive shifts and adapt ecosystem strategy accordingly.

IV. Launch Integration – Second Asset

• Co-develop Patient Commercial Strategy for Empa MMN launch with disciplined alignment to franchise strategy.
• Ensure Empa launch positioning complements and strengthens the in-market value of Vyvgart Hytrulo.
• Define sequencing, patient targeting, and differentiation strategy.
• Align US strategy with Global framework while advocating for market-specific needs.

V. Enterprise & Strategic Leadership

• Serve as a core strategic voice within the Indication Strategy Team.
• Shape portfolio priorities and resource allocation decisions.
• Provide executive-ready strategic recommendations supported by analytics and scenario modeling.
• Mentor high-performing patient marketing talent.
• Model enterprise mindset, cross-functional influence, and disciplined prioritization.

Core Competencies

· Enterprise Portfolio Optimization: Proven ability to maximize total franchise value.

· In-Market Growth Acceleration: Track record of driving revenue expansion in competitive markets.

· Patient Engagement & Commercial Strategy

· Dual-Asset Strategy & Lifecycle Planning

· Launch Excellence

· Market Shaping & Category Expansion

· Data-Driven Decision Making & Agile Optimization

· Executive Influence & Strategic Trade-Off Leadership

Qualifications

· 12-15+ years of biopharma commercial experience.

· Deep patient marketing expertise in specialty or rare disease markets preferred.

· Demonstrated success driving performance of an in-market brand.

· Launch experience required.

· Experience managing multi-asset or multi-indication portfolios strongly preferred.

· MBA or advanced degree preferred.

For applicants in the United States: The annual base salary hiring range for this position is $236,000.00 - $324,500.00 USD. This range reflects our good faith estimate at the time of posting. Individual compensation is determined using objective, inclusive, and job-related criteria such as relevant experience, skills, demonstrated competencies and internal equity. This means actual pay may differ from the posted range when justified by these factors. Because market conditions evolve, pay ranges are reviewed regularly and may be adjusted to remain aligned with external benchmarks.

This job is eligible to participate in our short-term and long-term incentive programs, subject to the terms and conditions of those plans and applicable policies. It also includes a comprehensive benefits package, including but not limited to retirement savings plans, health benefits and other benefits subject to the terms of the applicable plans and program guidelines.

At argenx, all applicants are welcomed in an inclusive environment. They will receive equal consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other applicable legally protected characteristics. argenx is proud to be an equal opportunity employer.

Before you submit your application, CV or any other personal details to us, please review our argenx Privacy Notice for Job Applicants to learn more about how argenx B.V. and its affiliates ("argenx") will handle and protect your personal data. If you have any questions or you wish to exercise your privacy rights, please contact our Global Privacy Office by email at View email address on click.appcast.io.

If you require reasonable accommodation in completing your application, interviewing, or otherwise participating in the candidate selection process please contact us at View email address on click.appcast.io. Only inquiries related to an accommodation request will receive a response.